1167053-13-5

Basic information

• Product Name: 6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinol
• Synonyms: 6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinol
• CAS NO: 1167053-13-5
• Molecular Formula: C₁₇H₂₂N₂O₄
• Molecular Weight: 318
• Mol File: 1167053-13-5.mol
• Article Data: 32

Chemical Properties

• Appearance: /
• Density: 1.220
• CAS DataBase Reference: 6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinol(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinol(1167053-13-5)
• EPA Substance Registry System: 6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinol(1167053-13-5)

Safety Data

• Hazardous Substances Data: 1167053-13-5(Hazardous Substances Data)

Usage

General Description

6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinol is a chemical compound with the molecular formula C22H26N2O4. It is an investigational drug that is being studied for its potential use in treating diseases such as cancer and other inflammatory conditions. 6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinol has shown promise in preclinical studies for its ability to inhibit tumor cell growth and suppress inflammation. It is a quinolinol derivative with a methoxy group at the 6 position and a morpholinylpropoxy group at the 7 position, and it is believed to exert its pharmacological effects through its interactions with specific cellular targets. Further research is needed to fully understand the potential therapeutic applications of this compound.

Upstream product

• 1449763-02-3 1-(4-(3-chloropropoxy)-5-methoxy-2-nitrophenyl)-3-(dimethylamino)propyl-2-en-1-one 
• 205448-32-4 4-chloro-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline 
• 58113-30-7 4-(3-chloropropoxy)-3-methoxyacetophenone 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 110-91-8 morpholine 
• 1394166-09-6 6-methyloxy-7-(4-(3-chloropropoxy))-4-4-hydroxyquinoline 
• 1394166-08-5 (Ε)-1-(4-(3-chloropropoxy)-5-methoxy-2-nitrophenyl)-3-(dimethylamino)propyl-2-en-1-one 
• 1160707-44-7 1-[4-(3-chloropropoxy)-5-methoxy-2-nitrophenyl]ethan-1-one 
• 1219937-97-9 1-[2-amino-5-methoxy-4-(3-morpholin-4-yl-propoxy)-phenyl]-ethanone 
• 109-94-4 formic acid ethyl ester 
• 1184831-17-1 1-[5-methoxy-4-(3-bromo-propoxy)-2-nitro-phenyl]-ethanone 
• 1394166-09-6 7-(3-chloropropyloxy)-6-methoxy-4(1H)-quinolinone 
• 205448-37-9 5-((3-(3-morpholinopropoxy)-4-methoxyanilino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 

Downstream Products

• 960299-44-9 4-(3-((4-(2-fluoro-4-nitrophenoxy)-6-methoxyquinolin-7-yl)oxy)propyl)morpholine 
• 479690-10-3 3-Fluoro-4-{[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy}-aniline 
• 849221-53-0 cyclopropane-1,1-dicarboxylic acid {3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-ylamino]-phenyl}-amide (4-fluoro-phenyl)-amide 
• 205448-32-4 4-chloro-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline 

Relevant articles and documents

Design, synthesis and anticancer evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 1,8-naphthyridine-3-carboxamide moiety as novel multi-target TKIs

Giving the fact that the disorders of multiple receptor tyrosine kinases (RTKs) are characteristics of various cancers, we assumed that developing novel multi-target drugs might have an advantage in treating the complex cancers. Taking the multi-target c-Met inhibitor Foretinib as the leading compound, we discovered a novel series of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 1,8-naphthyridine-3-carboxamide moiety with the help of molecular docking. Among them, the most promising compound 33 showed a prominent activity against Hela (IC50 = 0.21 μM), A549 (IC50 = 0.39 μM), and MCF-7 (IC50 = 0.33 μM), which were 3.28–4.82 times more active than that of Foretinib. Additionally, compound 33 dose dependently induced apoptosis by arresting A549 cells at G1 phase. Enzymatic assays and docking analyses were further confirmed that compound 33 was a multi-target inhibitor with the strong potencies against c-Met (IC50 = 11.77 nM), MEK1 (IC50 = 10.71 nM), and Flt-3 (IC50 = 22.36 nM). In the A549 cells mediated xenograft mouse model, compound 33 inhibited the tumor growth (TGI = 64%) without obvious toxicity, establishing compound 33 as a promising candidate for cancer therapy.

Novel substituted pyrazolo [1, 5-a] pyrimidine compound and preparation method and application thereof

The invention provides a novel substituted pyrazolo [1, 5-a]pyrimidine compound and a preparation method and application thereof, and particularly relates to a pyrazolo [1, 5-a]pyrimidine-containing quinoline derivative shown as a general formula (I) and pharmaceutically acceptable salts thereof, and substituent groups X, Ar and A have meanings given in the specification. The invention also relates to a compound represented by the general formula (I), wherein the compound has a strong c-Met kinase inhibition effect. The invention also relates to application of the compound and the pharmaceutically acceptable salt thereof in preparation of drugs for treating and/or preventing diseases caused by abnormal high expression of c-Met kinase, especially application in preparation of drugs for treating and/or preventing cancers.

Design, synthesis, and biological evaluation of 4-phenoxyquinoline derivatives as potent c-Met kinase inhibitor

A series of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydro-quinoxaline moiety were synthesized and evaluated for their antiproliferative activity against five human cancer cell lines (A549, H460, HT-29, MKN-45 and U87MG) in vitro. Most of the tested compounds exhibited more potent inhibitory activities than the positive control foretinib. Compound 1b, 1s and 1t were further examined for their inhibitory activity against c-Met kinase. The most promising compound 1s (with c-Met IC50 value of 1.42 nM) showed remarkable cytotoxicity against A549, H460, HT-29, MKN45 and U87MG cell lines with IC50 values of 0.39 μM, 0.18 μM, 0.38 μM, 0.81 μM, respectively. Their preliminary structure-activity relationships (SARs) study indicated that the replacement of the aromatic ring with the cyclohexane improved their antiproliferative activity.